MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
0.9259
-0.0147
-1.56%
Pre Market: 0.9494 +0.0235 +2.54% 06:00 07/27 EDT
OPEN
0.9325
PREV CLOSE
0.9406
HIGH
0.9856
LOW
0.8695
VOLUME
1.73K
TURNOVER
0
52 WEEK HIGH
12.23
52 WEEK LOW
0.8695
MARKET CAP
14.80M
P/E (TTM)
-0.1490
1D
5D
1M
3M
1Y
5Y
1D
Tempest Therapeutics inks China in vivo CAR-T deal
TipRanks · 4d ago
Tempest And Senlang To Collaborate To Develop Tempest’s Proprietary TPST-4003 Product Candidate, Beginning With IIT In China Evaluating TPST-4003 In ~10 Patients With MG Or MS; Expects First Patient Enrollment And Dosing To Occur In Q4 Of 2026
Benzinga · 5d ago
Tempest Therapeutics partners with Senlang Biotech to advance TPST-4003 in vivo CAR-T into first-in-human trial
PUBT · 5d ago
TEMPEST THERAPEUTICS - CO AND SENLANG TO DEVELOP TPST-4003 WITH TRIAL IN CHINA FOR MG AND MS
Reuters · 5d ago
Weekly Report: what happened at TPST last week (0713-0717)?
Weekly Report · 6d ago
Tempest Unveils Next-Gen In Vivo CAR-T Platform; To Advance TPST-4003 Into Q4 2026 Trial In MG, MS Patients
Benzinga · 07/15 11:04
Tempest Therapeutics plans first clinical study of in vivo CAR-T candidate TPST-4003 in Q4 2026
PUBT · 07/15 11:02
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 07/13 21:05
More
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company moving towards late-stage development with a portfolio of targeted and immune-mediated product candidates with the potential to be first-in-class to treat a range of cancers. Its programs range from early research to the lead program, amezalpat, a pivotal study in first-line hepatocellular carcinoma (HCC). Its second clinical program, TPST-1495, is a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 (PGE2), a pathway implicated in multiple cancers. Its development strategy for TPST-1495 includes evaluation in familial adenomatous polyposis (FAP), a rare genetic disorder that increases the risk of gastrointestinal cancers. Its pipeline also includes TPST-2003, TPST-2206, TPST-3003, and TPST-3206. TPST-2003 is a new dual-targeting CD19/BCMA CAR-T asset. TPST-2206 is a dual-targeting CD70/CD70 CAR-T for renal cell carcinoma. TPST-3206 is an allogeneic dual-targeting CD70/CD70.

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.